Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics

This article was originally published in The Pink Sheet Daily

Executive Summary

A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Advertisement

Related Content

COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
Taking Stock Of Qiagen
Taking Stock Of Qiagen
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Companion Diagnostics Move Toward Mainstream Drug Development
Vanda’s Fanapt Approval Is FDA U-Turn
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Biomarkers for Psychiatric Drugs: Outlier or Opportunity?

Topics

Advertisement
UsernamePublicRestriction

Register

PS070429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel